Log in

NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

$8.15
-0.09 (-1.09 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$8.05
Now: $8.15
$8.53
50-Day Range
$7.35
MA: $8.03
$9.00
52-Week Range
$5.96
Now: $8.15
$12.32
Volume106,241 shs
Average Volume94,829 shs
Market Capitalization$318.58 million
P/E RatioN/A
Dividend YieldN/A
Beta0.42
Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.97 million
Book Value$2.69 per share

Profitability

Net Income$-49,690,000.00
Net Margins-1,461.28%

Miscellaneous

Employees146
Market Cap$318.58 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.


Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) issued its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.02. The biopharmaceutical company earned $1.10 million during the quarter, compared to the consensus estimate of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%. View Kindred Biosciences' Earnings History.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

What price target have analysts set for KIN?

8 equities research analysts have issued twelve-month price objectives for Kindred Biosciences' shares. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' share price to reach $14.44 in the next twelve months. This suggests a possible upside of 77.1% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

What is the consensus analysts' recommendation for Kindred Biosciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Has Kindred Biosciences been receiving favorable news coverage?

Press coverage about KIN stock has trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kindred Biosciences earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Kindred Biosciences.

Are investors shorting Kindred Biosciences?

Kindred Biosciences saw a drop in short interest in November. As of November 15th, there was short interest totalling 815,100 shares, a drop of 8.3% from the October 31st total of 889,100 shares. Based on an average trading volume of 113,500 shares, the short-interest ratio is presently 7.2 days. Currently, 2.2% of the shares of the company are sold short. View Kindred Biosciences' Current Options Chain.

Who are some of Kindred Biosciences' key competitors?

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX), Cara Therapeutics (CARA), Opko Health (OPK), TherapeuticsMD (TXMD), Celgene (CELG), Corbus Pharmaceuticals (CRBP) and Global Blood Therapeutics (GBT).

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:
  • Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
  • Ms. Denise M. Bevers, Co-Founder, Pres, COO, Sec. & Director (Age 52)
  • Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
  • Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
  • Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Granahan Investment Management Inc. MA (1.90%), State Street Corp (1.65%), Silverback Asset Management LLC (1.38%), Dalton Greiner Hartman Maher & Co. (0.36%), Teton Advisors Inc. (0.09%) and Barclays PLC (0.05%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

Which institutional investors are selling Kindred Biosciences stock?

KIN stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC and Barclays PLC. View Insider Buying and Selling for Kindred Biosciences.

Which institutional investors are buying Kindred Biosciences stock?

KIN stock was bought by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Granahan Investment Management Inc. MA, Silverback Asset Management LLC, State Street Corp, Tower Research Capital LLC TRC, Metropolitan Life Insurance Co NY, Gabelli Funds LLC and Teton Advisors Inc.. View Insider Buying and Selling for Kindred Biosciences.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $8.15.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $318.58 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

What is Kindred Biosciences' official website?

The official website for Kindred Biosciences is http://kindredbio.com/.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]


MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  628
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel